{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:35:09Z","timestamp":1777469709085,"version":"3.51.4"},"reference-count":129,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2015,6,3]]},"DOI":"10.1517\/13543776.2015.1041921","type":"journal-article","created":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T02:44:10Z","timestamp":1430880250000},"page":"629-642","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Products for the treatment of inflammatory bowel disease: a patent review (2013 \u2013 2014)"],"prefix":"10.1517","volume":"25","author":[{"given":"Luiz C","family":"Di Stasi","sequence":"first","affiliation":[{"name":"S\u00e3o Paulo State University (UNESP), Institute of Biosciences, Department of Pharmacology, Laboratory of Phytomedicines, Pharmacology and Biotechnology (PhytoPharmaTech)","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso ARA","family":"Costa","sequence":"additional","affiliation":[{"name":"S\u00e3o Paulo State University (UNESP), Institute of Biosciences, Department of Pharmacology, Laboratory of Phytomedicines, Pharmacology and Biotechnology (PhytoPharmaTech)","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Witaicenis","sequence":"additional","affiliation":[{"name":"S\u00e3o Paulo State University (UNESP), Institute of Biosciences, Department of Pharmacology, Laboratory of Phytomedicines, Pharmacology and Biotechnology (PhytoPharmaTech)","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.02.026"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.158"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10208"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/35079114"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S33961"},{"key":"e_1_3_2_8_1","article-title":"Vedolizumab in the treatment of Crohn\u2019s disease","author":"Gisbert JP","year":"2015","unstructured":"Gisbert JP, Domenech E. Vedolizumab in the treatment of Crohn\u2019s disease. Gastroenterol Hepatol 2015. [Epub ahead of print]","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300934"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.91"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.044"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S65979"},{"key":"e_1_3_2_13_1","article-title":"Biological therapy for ulcerative colitis","author":"Arora Z","year":"2014","unstructured":"Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2014; Epub ahead of print","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.103564"},{"key":"e_1_3_2_15_1","unstructured":"Forbes W Borte E Johnson L et al. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males. Salix Pharmaceuticals Ltd. US8497256B2; 2013"},{"key":"e_1_3_2_16_1","unstructured":"Pravda J. Methods for treatment for ulcerative colitis in mammals. Therapeutic Research LLC. USPTO8476233; 2013"},{"key":"e_1_3_2_17_1","unstructured":"Lichtenberger LM. Preparations of pharmaceuticals containing 5-amino salicylic acid and phospholipids for treatment of inflammatory bowel disease. Board Of Regents Of The University Of Texas System. JPO2014015478; 2014"},{"key":"e_1_3_2_18_1","unstructured":"Wolfe HRE. Therapeutic peptides. Combimab Inc. USPTO8748575; 2014"},{"key":"e_1_3_2_19_1","unstructured":"Shailubhai K. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders inflammation cancer and other disorders. Synergy Pharmaceuticals Inc. USPTO8569246; 2013"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S32252"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(99)00033-6"},{"issue":"4","key":"e_1_3_2_22_1","first-page":"403","article-title":"Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation","volume":"9","author":"Harris LA","year":"2007","unstructured":"Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007;9(4):403-10","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198706000-00009"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.1.83"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016139"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031686"},{"key":"e_1_3_2_27_1","unstructured":"Barbera Betancourt A del Carmen Dominguez Horta M Lorenzo Perez N et al. Method of inducing T cell apoptosis by administering Altered Peptide Ligand. Cuba; Centro de Ingenieria Genetica y Biotecnologia. USPTO8410057; 2013"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001090100259"},{"key":"e_1_3_2_29_1","unstructured":"Paterson B Tamiz A Pandey N et al. Use of tight junction antagonists to treat inflammatory bowel disease. Alba Therapeutics Corp. USPTO8796203; 2014"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06538.x"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.4161\/tisb.27321"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.150888"},{"key":"e_1_3_2_33_1","unstructured":"Wu TC. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease. Holy Stone Healthcare Co. Ltd. USPTO8575130; 2013"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2006.05.009"},{"key":"e_1_3_2_35_1","unstructured":"Xu YZ Yuan S Wone D et al. Pyridinone antagonists of alpha-4 integrins. Elan Pharmaceuticals Inc. USPTO8367836; 2013"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023394737"},{"key":"e_1_3_2_37_1","unstructured":"Greene MI Hancock MW Katsumata M et al. Therapy of autoimmune colitis using a TIP60 inhibitor. The Trustees Of The University Of Pennsylvania The Children\u2019s Hospital of Philadelphia. USPTO8497285; 2013"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.04.021"},{"key":"e_1_3_2_39_1","unstructured":"DeLuca HF Clagett-Dame M Plum LA et al. A-ring modified 19-nor-vitamin D analogs and their uses. Wisconsin Alumni Research Foundation. USPTO8785422; 2014"},{"key":"e_1_3_2_40_1","unstructured":"Ganapathy V Prasad PD Martindale RG et al. Prodrugs of short-chain fatty acids and treatment methods. Georgia Health Sciences University Research Institute Inc. USPTO8518989; 2013"},{"key":"e_1_3_2_41_1","unstructured":"Haller D Hormannsperger G. Lactocepins for use in the treatment of IP-10-mediated inflammatory diseases. Technische Universitat Munchen. WO0209411; 2013"},{"key":"e_1_3_2_42_1","unstructured":"Tracey KJ Wang H. Inhibition of inflammation using \u03b17 receptor-binding cholinergic agonist. North Shore-Long Island Jewish Research Inst. JPO2014055178; 2014"},{"key":"e_1_3_2_43_1","unstructured":"Yamamuro N Nakamaru K Yasue T. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient. North Shore-Long Island Jewish Research Inst. JPO2014055178; 2014"},{"key":"e_1_3_2_44_1","unstructured":"Takanao O. Hirotsugu c\/o Astellas Pharma Inc; UEDA Keiko c\/o Astellas Pharma Inc. Compound WS727713. Telsar Pharma Inc. JPO2014040456; 2014"},{"key":"e_1_3_2_45_1","unstructured":"Yamamoto A Nasu R Ito Y. Composition for preventing and\/or treating colonic inflammatory disease. Kaigen Pharma Co. Ltd. JPO2014009179; 2014"},{"key":"e_1_3_2_46_1","unstructured":"Tsutsumi Y Yoshioka Y Yoshikawa T et al. Preventive or therapeutic agent for inflammatory bowel disease. Vitamin C60 Bioresearch Kk. Osaka Univ. JPO2013087108; 2013"},{"key":"e_1_3_2_47_1","unstructured":"Sheridan H Frankish N. Indene derivatives for use in the treatment of inflammatory bowel disease. Venantius Ltd. EP2734496A1; 2013"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.07.008"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(02)80176-1"},{"issue":"1","key":"e_1_3_2_50_1","first-page":"S1","article-title":"Scientific concepts of functional foods in Europe. Consensus document","volume":"81","author":"Diplock AT","year":"1999","unstructured":"Diplock AT, Ashwell M, Bomet F, et al. Scientific concepts of functional foods in Europe. Consensus document. Br J Nutr 1999;81(Suppl 1):S1-27","journal-title":"Br J Nutr"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20737"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201402700418"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.3920\/BM2014.0070"},{"issue":"4","key":"e_1_3_2_54_1","first-page":"929","article-title":"Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease","volume":"12","author":"Shadnoush M","year":"2013","unstructured":"Shadnoush M, Shaker Hosseini R, Mehrabi Y, et al. Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease. Iran J Pharm Res 2013;12(4):929-36","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03434.x"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2013.01.006"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i33.11505"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2296-0"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/125.6.1401"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001574-200003000-00013"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i41.15163"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2014.01.111"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665114000639"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/435268"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12087"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0777-2"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2013.03.011"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0115426506021004351"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2009.07.022"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R036012"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.02.018"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25599"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25638"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03562.x"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1990.70.2.567"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(82)80339-9"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2010.07.009"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2744-4"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i4.550"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2164(04)54010-8"},{"key":"e_1_3_2_81_1","unstructured":"Raso E Lapis K. Use of fermented wheat germ in the treatment of inflammatory bowel disease. 3 CH Ltd. Raso Erzsebet; Lapis Karoly. WO2012159988; 2014"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2008.0486"},{"issue":"3","key":"e_1_3_2_83_1","first-page":"325","article-title":"Effect of Avemar\u2013a fermented wheat germ extract\u2013on rheumatoid arthritis. Preliminary data","volume":"24","author":"Balint G","year":"2006","unstructured":"Balint G, Apathy A, Gaal M, et al. Effect of Avemar\u2013a fermented wheat germ extract\u2013on rheumatoid arthritis. Preliminary data. Clin Exp Rheumatol 2006;24(3):325-8","journal-title":"Clin Exp Rheumatol"},{"issue":"37","key":"e_1_3_2_84_1","first-page":"1925","article-title":"Fermented wheat germ extract in the supportive therapy of colorectal cancer","volume":"146","author":"Farkas E","year":"2005","unstructured":"Farkas E. Fermented wheat germ extract in the supportive therapy of colorectal cancer. Orv Hetil 2005;146(37):1925-31","journal-title":"Orv Hetil"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601153"},{"issue":"32","key":"e_1_3_2_86_1","first-page":"393","article-title":"First clinical data of a natural immunomodulator in colorectal cancer","volume":"47","author":"Jakab F","year":"2000","unstructured":"Jakab F, Mayer A, Hoffmann A, et al. First clinical data of a natural immunomodulator in colorectal cancer. Hepatogastroenterology 2000;47(32):393-5","journal-title":"Hepatogastroenterology"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12349-008-0008-4"},{"key":"e_1_3_2_88_1","unstructured":"MacSharry J O\u2019Mahony L O\u2019Sullivan D et al. Probiotic bifidobacterium strains. Alimentary Heath Ltd. USPTO8557233; 2013"},{"key":"e_1_3_2_89_1","unstructured":"Mojca Lunder L Ravnikar M Strukelj B et al. Modified food grade microorganism for treatment of inflammatory bowel disease. University of Ljubljana; Institute Jozef Stefan; Labena d.o.o. US8754198B2; 2014"},{"key":"e_1_3_2_90_1","unstructured":"Veiga P Chambaud I Khlebnikov A et al. Method for reducing gastro-intestinal inflammation using Bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria. Compagnie Gervais Danone; President and Fellows of Harvard College. USPTO8685388; 2014"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114509990882"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1011737107"},{"key":"e_1_3_2_93_1","unstructured":"Israelsen H. Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effector. Nordisk Rebalance As. JPO2013144712; 2013"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000437046.26036.db"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i15.1773"},{"key":"e_1_3_2_96_1","unstructured":"Daisuke M Asama T Motoki H et al. New lactic acid bacteria having promotion activity for IgA production and use of the same. Yamada Bee Co. Inc. JPO2014073130; 2013"},{"key":"e_1_3_2_97_1","unstructured":"Saburo M Tomohiro O Hiroyuki S et al. Inflammatory bowel disease inhibitor and food and drink. Tottori Univaon Chemical Kkota Suten:Kktottori Institute of Industrial Technology. JPO2013180958; 2013"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2012.10.010"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640614550672"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i3.293"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300904"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-014-0113-2"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.09.016"},{"key":"e_1_3_2_104_1","unstructured":"McKenzie ANJ Neill D. Antibodies against IL-17BR. Medical Research Council. USPTO8586037; 2013"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0591-2"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211798357872"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.05.001"},{"key":"e_1_3_2_108_1","unstructured":"Shibuya A Oda C Iino S et al. Medicine comprising active modulator of CD300a-expressing cell associated with inflammatory bowel disease CD300aa gene knock-out mouse and use of active modulator of CD300a-expressing cell. University of Tsukuba. JPO2014094898; 2014"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-13-23"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep05412"},{"key":"e_1_3_2_111_1","unstructured":"Pickford LB Bebbington CR Yarranton GT et al. Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist. Medarex L.L.C. USPTO8828393; 2014"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.3.425"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1994.14.235"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301093"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12195"},{"key":"e_1_3_2_116_1","unstructured":"Monteleone G. Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field. Nogra Pharma Ltd. USPTO8648186; 2014"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2012.11.011"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i40.5664"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.290"},{"key":"e_1_3_2_120_1","unstructured":"Frey MR. Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis. Children\u2019s Hospital Los Angeles. EP2744512A1; 2013"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-008-7440-8"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.400846"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.06.015"},{"key":"e_1_3_2_124_1","unstructured":"Weinstock JV Elliot DE. Use of parasitic biological agents for prevention and control of autoimmune diseases. University of Iowa Research Foundation. JPO2014129390; 2014"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.1.270"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.02.011"},{"issue":"4","key":"e_1_3_2_127_1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.146.4.1322","article-title":"Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni","volume":"146","author":"Grzych JM","year":"1991","unstructured":"Grzych JM, Pearce E, Cheever A, et al. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni. J Immunol 1991;146(4):1322-7","journal-title":"J Immunol"},{"issue":"4","key":"e_1_3_2_128_1","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4049\/jimmunol.153.4.1707","article-title":"IL-12 inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni","volume":"153","author":"Oswald IP","year":"1994","unstructured":"Oswald IP, Caspar P, Jankovic D, et al. IL-12 inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. J Immunol 1994;153(4):1707-13","journal-title":"J Immunol"},{"key":"e_1_3_2_129_1","unstructured":"Zhang C Li Y Xu Y et al. Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases. Suzhou Sciscape Biomedicine Science & Technology Co. Ltd. Chenggang Zhang Junhuai LI Yang Xu Yonghong Wu Weiguang Li Yanchun Zhang Yan Gao Zhihui Li Institute Of Radiation Medicine Academy Of Military Medical Sciences People\u2019s Liberation Army Of China. EP2730287A1; 2013"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.3.1609"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200420295"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543776.2015.1041921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:35:24Z","timestamp":1770413724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543776.2015.1041921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6,3]]}},"alternative-id":["10.1517\/13543776.2015.1041921"],"URL":"https:\/\/doi.org\/10.1517\/13543776.2015.1041921","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}